# Comment on Hasan et al. Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma. Clin. Pract. 2023, 13, 806–819

**Authors:** Stefan Harsanyi, Zuzana Varchulova Novakova, Stanislav Ziaran, Lubos Danisovic, Katarina Bevizova

PMC · DOI: 10.3390/clinpract16010009 · Clinics and Practice · 2025-12-31

## Full-text entities

- **Genes:** CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** Urothelial Bladder Carcinoma (MESH:D001749)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12839979/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC12839979/full.md

---
Source: https://tomesphere.com/paper/PMC12839979